RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States.
$76.42+0.50%
报价 2026-11-13
市值
$6.02B
EV
$7.57B
PE (TTM)
–
预期 PE (FY2026)
149.8x
52 周区间距高点 -9.5%
$51.87$84.48
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | 0.54 → 0.87（1.6x） | 87.8 |
| FY+32028-12 | 1.3x | 0.54 → 1.12（2.1x） | 68.2 |
毛利率 10% · TTM 收入 $2384M · 基数 EPS 0.54（调整后）
电话会信号
辅助标签Q3 20262026-11-09
扩产需求加速AI 词频高积压订单词频高上调指引供不应求
指引 上调
信心 5
分析师 4
“We are on track for more than $140 million of ARR by year-end, roughly 87% growth over 2025.”
原文引用（4）
- 扩产：we certainly have added an enormous amount of capacity
- 需求加速：The demand continues to accelerate
- 上调指引：we elected to again increase our 2026 full year guidance ranges for imaging center revenue, adjusted EBITDA and free cash flow
- 供不应求：imaging demand outpacing the supply of trained radiologists
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
L2 2026-07-06全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RDNTRadNet, Inc. | $6.02B | +0.5% | +25.3% | 13.5% | – | 25.6x | – | |
| BTSGBrightSpring Health Services, Inc. Common Stock | $14.17B | -0.3% | +25.7% | 12.3% | 40.9x | 21.2x | 27.1x | |
| BRKRBruker Corporation | $9.41B | +2.1% | +3.4% | 49.1% | – | 90.1x | 38.9x | |
| KRYSKrystal Biotech, Inc. | $9.05B | -0.1% | +28.4% | 92.6% | 35.3x | 40.7x | 29.2x | |
| BLCOBausch + Lomb Corporation | $7.54B | -0.2% | +8.2% | 60.5% | – | 17.6x | 29.5x | |
| CHEChemed Corporation | $7.13B | -0.4% | +7.2% | 31.1% | 19.7x | 12.6x | 24.1x | |
| TFXTeleflex Incorporated | $6.15B | +1.3% | -31.3% | 53.3% | – | 63.6x | 15.9x | |
| MMSIMerit Medical Systems, Inc. | $5.19B | -0.1% | +8.4% | 48.7% | 31.5x | 13.5x | 25.4x | |
| SHCSotera Health Company | $4.74B | +1.9% | +7.3% | 55.4% | 34.1x | 13.9x | 49.5x | |
| 同行中位数 | – | – | +7.8% | 51.2% | 34.1x | 19.4x | 28.2x |
研究全文
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $638.3M | $622.7M | $575.6M | $547.7M | $522.9M | $498.2M | $471.4M | $477.1M |
| Gross Margin | 13.5% | 14.1% | -2.8% | 13.9% | 13.9% | 13.9% | 3.8% | 13.8% |
| Operating Margin | 4.7% | 6.3% | -2.8% | 6.4% | 6.3% | 6.2% | -5.1% | 5.1% |
| Net Income | $4.2M | $7.5M | $-33.5M | $-597,000 | $5.4M | $14.5M | $-37.9M | $5.3M |
| Diluted EPS | 0.05 | 0.1 | -0.43 | -0.01 | 0.07 | 0.19 | -0.51 | 0.07 |
| Operating Cash Flow | $90.6M | $87.8M | $79M | $84.2M | $52.8M | $120.3M | $41.5M | $42.5M |